18 and older, any sex, with Hepatocellular Carcinoma or Liver Cancer. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Tumor ResponsePrimary· Up to 2 years
A modified Response Evaluation Criteria In Solid Tumors (RECIST) will be used. The modification to RECIST is that although all lesions will be followed, only the treated lesions will be included in the assessment of response. Additionally, all lesions will be evaluated according to the following criteria: Presence of arterial enhancement: Yes or No. Complete Response (CR) = Absence of enhancing tumor areas, reflecting complete tissue necrosis. Partial Response (PR) = A decrease \> 50% of enhanced areas, reflecting partial tissue necrosis. Stable Disease (SD) = A tumor response between PR and P
CR
Group
Value
95% CI
Cisplatin + Mitomycin-C
0
PR
Group
Value
95% CI
Cisplatin + Mitomycin-C
7
SD
Group
Value
95% CI
Cisplatin + Mitomycin-C
47
PD
Group
Value
95% CI
Cisplatin + Mitomycin-C
11
Inevaluable for Response
Group
Value
95% CI
Cisplatin + Mitomycin-C
11
Number of Participants With Grade 3 or Higher ToxicitySecondary· Up to 1 year
Toxicity will be assessed according to CTCAE version 3.0
Group
Value
95% CI
Cisplatin + Mitomycin-C
75
Adverse events — posted to ClinicalTrials.gov
Time frame: Up to 1 year.
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
Cisplatin + Mitomycin-C
Serious: 51/76 (67%)
Deaths: 44/76
Serious adverse events (29 terms)
Reaction
System
Cisplatin + Mitomycin-C
Platelets
Blood and lymphatic system disorders
—
Neutrophils/granulocytes (ANC/AGC)
Blood and lymphatic system disorders
—
Fatigue (asthenia, lethargy, malaise)
General disorders
—
Alanine aminotransferase increased
Investigations
—
Aspartate aminotransferase increased
Investigations
—
Abdominal pain
Gastrointestinal disorders
—
Nausea
Gastrointestinal disorders
—
Vomiting
Gastrointestinal disorders
—
Anorexia
General disorders
—
Blood bilirubin increased
Investigations
—
Hyperglycemia
Metabolism and nutrition disorders
—
Leukocytes
Blood and lymphatic system disorders
—
Hemoglobin
Blood and lymphatic system disorders
—
Dehydration
Gastrointestinal disorders
—
Diarrhea
Gastrointestinal disorders
—
Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L)
General disorders
—
Constipation
Gastrointestinal disorders
—
Esophageal hemorrhage
Gastrointestinal disorders
—
Lower gastrointestinal hemorrhage
Gastrointestinal disorders
—
Liver dysfunction/failure (clinical)
Hepatobiliary disorders
—
Edema limb
General disorders
—
Alkaline phosphatase increased
Investigations
—
Creatinine increased
Investigations
—
Hyperkalemia
Metabolism and nutrition disorders
—
Hyponatremia
Metabolism and nutrition disorders
—
Other adverse events (72 terms — click to expand)
Reaction
System
Cisplatin + Mitomycin-C
Hemoglobin decreased
Blood and lymphatic system disorders
—
Fatigue (asthenia, lethargy, malaise)
General disorders
—
Anorexia
Gastrointestinal disorders
—
Bilirubin (hyperbilirubinemia)
Metabolism and nutrition disorders
—
Platelets decreased
Blood and lymphatic system disorders
—
Nausea
Gastrointestinal disorders
—
AST (SGOT) increased
Metabolism and nutrition disorders
—
Alkaline phosphatase increased
Metabolism and nutrition disorders
—
ALT (SGPT) increased
Metabolism and nutrition disorders
—
Edema: limb
General disorders
—
Pain (Abdomen NOS)
Gastrointestinal disorders
—
Neutrophils/granulocytes (ANC/AGC)
Blood and lymphatic system disorders
—
Dizziness
Nervous system disorders
—
Albumin, serum-low (hypoalbuminemia)
Metabolism and nutrition disorders
—
Glucose, serum-high (hyperglycemia)
Metabolism and nutrition disorders
—
Diarrhea
Gastrointestinal disorders
—
Vomiting
Gastrointestinal disorders
—
Creatinine increased
Metabolism and nutrition disorders
—
Dyspnea (shortness of breath)
Respiratory, thoracic and mediastinal disorders
—
Fever (in the absence of neutropenia, where neutropenia is defined as ANC <1.0 x 10e9/L)
This study is for people with cancer of the liver that cannot be completely removed by surgery. This study involves giving the drugs mitomycin-C and cisplatin, into an artery in the liver. Mitomycin-C is a drug that has been approved by the FDA to treat cancer of the stomach and pancreas. Mitomycin-C is a drug that causes cancer cells to die and prevents them from reproducing. Cisplatin is also a drug that has been approved by the FDA. Cisplatin is approved to treat cancer of the testes, ovaries, lung, esophagus, bladder, head and neck. Cisplatin is a drug that prevents cancer cells from reproducing. The purpose of this study is to see how long it takes subjects' tumor(s) to grow after receiving the study drugs. Another purpose of this study is to look at the side effects of this study therapy and how long subjects survive after receiving it.
An additional purpose of this study is to see how well we can predict subjects' response to the study therapy, based on blood and tumor tissue tests. These tests will measure the levels of genes (the cell's blueprint) in subjects' tumors and blood. These genes affect how people's bodies react to the cancer drugs.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
NCT07417397 — Adjuvant TACE in HCC With High-risk Recurrence Factors
· Phase 3
· recruiting
NCT07317414 — β-alanine in the Treatment of Advanced Hepatocellular Carcinoma
· Phase 2
· recruiting
NCT07148050 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimer
· Phase 1
· recruiting
Other University of Southern California trials
Trials by the same sponsor.
NCT07288463 — Hearing Loss and Genetic Risks for Alzheimer's Disease and Related Dementia
· NA
· not yet recruiting
NCT05914233 — Non-invasive Ultrasound Retinal Stimulation for Vision Restoration
· NA
· not yet recruiting
NCT06163664 — Role of ChatGPT in Vestibular Schwannoma Management
· NA
· withdrawn
NCT07332312 — A Culturally Informed Patient Navigation Program (CFPN) to Reduce Delays Between Diagnosis and Treatment in American Ind
· NA
· not yet recruiting
NCT07290478 — Encouraging Older Adults and Adults With Serious Illness to Designate a Health Care Proxy
· NA
· not yet recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Southern California
Last refreshed: 30 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00183885.